Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral ...
Shares of vTv Therapeutics rose after the Food and Drug Administration lifted a clinical hold on its diabetes treatment program. The stock gained 40% to $20.78 Monday morning. Shares have climbed ...
Current FDA approval of this adaptive system is for the treatment of Parkinson’s only, not essential tremor, dystonia (a ...
Verywell Health on MSN15m
Does ‘Nature’s Ozempic’ Exist? What Science Says About Natural AlternativesMedically reviewed by Karina Tolentino, RD Various plants, herbs, and substances are being called “nature’s Ozempic,” usually ...
Amicus Therapeutics benefits from strong revenue and limited competition. Learn why FOLD stock is a BUY, with a favorable ...
Zacks Small Cap Research on MSN32m
NRXBF Test Results Bolster ProspectsNRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback